Navigation Links
Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
Date:7/31/2008

as 27 weeks for platinum-refractory and -resistant SCLC patients, a population for which there are very few treatment options.

-- Colorectal Cancer: Completed enrollment in our randomized, controlled Phase 2 trial in patients with CRC and presented positive preliminary results from this study at ASCO. Preliminary data suggested that picoplatin given once every four weeks in combination with 5-fluorouracil and leucovorin in the FOLPI regimen may have similar anti-tumor activity to oxaliplatin in combination with 5-fluorouracil and leucovorin in the FOLFOX regimen, which is the current standard of care in the first-line treatment of CRC.

We also presented expanded and updated results from our Phase 1 dose-escalation study in patients with CRC treated with FOLPI treatment administered every two or four weeks. None of the patients treated with picoplatin at doses of up to a cumulative dose of 1,350 mg/m2 exhibited severe neuropathy (Grade 3 or 4) in 62 evaluable patients. Current use of FOLFOX in CRC patients is associated with substantial neurotoxicity related to increasing cumulative doses of oxaliplatin at greater than 800 mg/m2. In addition, nephrotoxicities and ototoxicities were rare and mild with the FOLPI regimen.

-- Prostate Cancer: Presented preliminary safety and efficacy at ASCO data from our ongoing Phase 2 clinical trial of picoplatin in combination with docetaxel and prednisone, the standard of care for the first-line treatment of HRPC. Results to date demonstrated that picoplatin can be safely administered at full-dose docetaxel. Prostate specific antigen levels, or PSA normalized in 23 percent of patients. The data also demonstrated that reductions in PSA of at least 50 percent were achieved in 69 percent of evaluable patients. This compares favorably to published docetaxel treatment PSA response rates of approximately 45 percent.

-- Ovarian and Other Advanced Solid Tumors: Announced positive safety and efficacy data at ASCO
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Poniard Pharmaceuticals Announces Upcoming Conference Participation
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... County, NY (PRWEB) September 22, 2014 ... joined the Department of Surgery at the Icahn School ... Sinai Doctors New York Group for Plastic Surgery gives ... Valley access to a team of world-renowned plastic surgeons ... Additionally, C. Andrew Salzberg, MD, who led NYGPS, was ...
(Date:9/22/2014)... very familiar "lub-dub" pattern that speeds up or slows ... itself isn,t as regular as you might think. In ... even at a "constant" heart rateand that variability, doctors ... heart rate variability (HRV) has been found to be ... heart failure and inflammation. For athletes, a drop in ...
(Date:9/22/2014)... WHO: LiveOps, Inc., the global ... solutions. , WHAT: The 10th annual Customer Response ... for the connected consumer. Constant change in technology ... challenges and opportunities for customer experience executives. The ... practices, network and learn from fellow attendees, speakers ...
(Date:9/22/2014)... By Tara Haelle ... (HealthDay News) -- Measuring how quickly a child,s brain ... according to a new study. Observing children,s ... is currently possible, the study authors reported. "The ... information is associated with autism severity is hugely promising," ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Medical ... for a three-day conference to discuss brain-related diseases ... injury from concussions and neurodegenerative disorders. , ... director affiliated with a Silverado memory care community ... dedicated expertise in memory care, hosts the annual ...
Breaking Medicine News(10 mins):Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 3Health News:Variability keeps the body in balance 2Health News:Variability keeps the body in balance 3Health News:Variability keeps the body in balance 4Health News:LiveOps To Lead Panel Discussion At Customer Response Summit Memphis 2Health News:Brainwaves May Help Gauge Autism Severity: Study 2Health News:Brainwaves May Help Gauge Autism Severity: Study 3Health News:Brainwaves May Help Gauge Autism Severity: Study 4Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 2Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 3
... offers a low cost, non-invasive alternative to conventional ... having coronary artery disease; true even if the ... a study performed at the Thomas Jefferson University ... patients who had one or more calcified coronary ...
... shown that babies exposed to tobacco in utero are ... are at increased risk for sudden infant death syndrome. ... these babies are also less likely to self-soothe and ... did not smoke during pregnancy. , Researchers from The ...
... the leading,provider of internet and digital information accessibility ... award-winning System Access,software. With this release, Serotek ... support for 64-bit operating systems. This is ... IT professionals,alike. , ...
... ROME, N.Y., Dec. 1 To help prevent the spread ... is using two new,products that kill germs on hands and ... According to Infection Prevention Director LeAnna Grace, the hospital,conducted a ... sanitizing lotion to evaluate how well they work and was ...
... is a statement from Jeff Levi, Ph.D., Executive Director of ... and Drug Administration,s (FDA) progress report on the Food Protection ... lacks a real plan for food protection. The staff ... some key initiatives to improve food safety, but they can ...
... Pressure BioSciences, Inc. (Nasdaq: PBIO ) ("PBI" or ... significantly reduce costs, centralize core operations, and refocus the Company,s ... found significant market acceptance. The restructuring program includes: , ... personnel of eight full-time employees (40% of the workforce) , ...
Cached Medicine News:Health News:Newborns exposed to maternal smoking more irritable, difficult to soothe 2Health News:Serotek First to Offer 64-Bit Support 2Health News:MRSA and C. difficile Infections Reduced by 50% in Hospital Study 2Health News:MRSA and C. difficile Infections Reduced by 50% in Hospital Study 3Health News:TFAH Statement: FDA Food Protection Plan is Insufficient 2Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 2Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 3Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 4Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 5Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 6Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 7
(Date:9/22/2014)... , Sept. 22, 2014  Neuralstem, Inc. (NYSE MKT: ... site investigator at Emory University, presented long-term follow up ... neural stem cells in the treatment of amyotrophic lateral ... presentation, which occurred at the Annual Symposium on ALS ... , on Friday, and was not open to ...
(Date:9/22/2014)... , Sept. 22, 2014  Olympus, a global ... for medical and surgical procedures, among other core ... with Munich -based Brainlab to ... Navigation. This agreement applies to the US ... U.S. sales and all distribution outside the U.S. ...
(Date:9/22/2014)... 22, 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... a phase I clinical trial in patients with ... tolerability, and immunogenicity of INO-3106. This immunotherapy targets ... aerodigestive cancers. Aerodigestive cancers affect the ... parts of the esophagus and windpipe. The unmet ...
Breaking Medicine Technology:Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 3Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 4Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 2Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 3Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 4Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4
... FOREST, Ill., Sept. 6, 2011 Hospira, Inc. ... in generic injectable pharmaceuticals, today announced positive results from ... erythropoietin (EPO) in patients with renal (kidney) dysfunction who ... equal pharmacokinetics, or blood level and distribution in the ...
... 2011 Johnson & Johnson (NYSE: JNJ ) ... Tuesday, September 13 th , at the Grand Hyatt New ... New York, NY.  Dominic Caruso, Vice President, Finance and Chief ... the company in a session scheduled at 10:20 a.m. (Eastern). ...
Cached Medicine Technology:Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients 2Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients 3
... a range of Milli-Q ultrapure water ... quality requirements. Each of the five ... specifically target contaminants detrimental to particular ... and ICP-MS. The systems incorporate a ...
... Millipore has developed a range ... to match specific water quality requirements. ... systems is designed to specifically target ... as HPLC, molecular biology and ICP-MS. ...
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... has developed a range of Milli-Q ... specific water quality requirements. Each of ... designed to specifically target contaminants detrimental ... molecular biology and ICP-MS. The systems ...
Medicine Products: